MHRA's first two centralised programmes are focusing on software or AI used as a medical device (SaMD/AIaMD) and the use of ...

The US FDA issued similar warning letters to five different online peptide vendors on 24th August, giving the companies 15 ...

Custom autologous cell therapies face immense manufacturing bottlenecks, steep financial costs, and vein-to-vein logistical ...

PMV Pharma is preparing to file for approval of its oral p53 protein reactivator drug rezatopopt in the first quarter of 2027 ...

The US Advanced Research Projects Agency for Health (ARPA-H) has awarded $125 million in funding, split across five groups, ...

Novartis has paused eight clinical trials of its experimental CAR-T therapy rapcabtagene autoleucel (rap-cel or YTB323) after ...

Novartis' oral BTK inhibitor remibrutinib has shown efficacy in a pair of phase 3 trials in relapsing multiple sclerosis (RMS ...

Nine mid-sized pharma companies have signed up for the Trump administration's Most Favoured Nation (MFN) pricing deals, ...

AstraZeneca and Daiichi Sankyo's Enhertu, given in combination with Roche's Perjeta, has become the first new frontline ...

GSK is planning to start a phase 3 trial of the new vaccine later this month, saying it will be the first late-stage trial of ...

Roche is paying $75 million for a trispecific antibody developed by a subsidiary of China's Simcere Pharma as a treatment for ...

Takeda and Protagonist Therapeutics' hepcidin mimetic rusfertide has been approved by the FDA to treat polycythaemia vera (PV ...